Rituximab

Aetna covers rituximab products (Rituxan, Truxima, Riabni, Ruxience, Rituxan Hycela) for confirmed CD20‑positive B‑cell oncologic disorders, but prefers Truxima as the lower‑cost agent and limits use of other brands to cases with contraindication, intolerance, or inadequate response to Truxima; Rituxan Hycela is not for non‑malignant conditions and may only be initiated after at least one tolerated IV rituximab dose. Precertification with a Statement of Medical Necessity is required for all listed rituximab products, and RA dosing requests are not covered if planned less than 16 weeks since the prior dose.

"Siliq (brodalumab): Plaque psoriasis"

Sign up to see full coverage criteria, indications, and limitations.